INTRODUCTION
============

It is now well-appreciated that there are several modes of cell death in higher organisms ([@B31]). Among them, apoptosis represents a key cellular program which is associated with a number of characteristic biochemical features as well as morphological parameters ([@B31]). The efficacy of most anticancer therapies resides in their ability to engage endogenous cell death programs in cancer cells ([@B15]). This implies that a blockade of cell death pathways provides an effective means to evade the cytotoxicity of current treatment approaches. Thus, a better understanding of the molecular events that are responsible for the dysregulation of cell death signaling networks in pediatric malignancies is expected to open new opportunities for the development of innovative treatment strategies.

APOPTOSIS SIGNALING NETWORKS
============================

A core apoptotic machinery is responsible for the initiation and execution of programmed cell death by apoptosis ([@B15]). Accordingly, the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway represent the two principal signaling cascades that fuel into the activation of a common downstream effector route of apoptosis that eventually leads to the dismantling of the cell (**Figure [1](#F1){ref-type="fig"}**; [@B15]). In the executioner phase of apoptosis, a family of proteases, i.e., caspases, represent core effector molecules of apoptosis that contribute to the final steps of apoptotic cell death by cleaving key cellular substrates, for example components of the cytoskeletal apparatus and nuclear DNA ([@B42]).

![**Scheme of apoptosis pathways**. There are two key apoptosis signaling pathways, i.e., the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway. Stimulation of death receptors by their cognate ligands leads to activation of caspase-8, which either directly activates downstream caspases or initiates the mitochondrial pathway by cleaving Bid. Engagement of the intrinsic pathway results in the release of mitochondrial proteins such as cytochrome c or Smac into the cytosol, which in turn promotes activation of caspase-3 and apoptosis.](fonc-03-00022-g001){#F1}

As far as the death receptor (extrinsic) pathway of apoptosis is concerned, the binding of soluble ligands of the tumor necrosis factor (TNF) family of ligands or agonistic antibodies to death receptors of the TNF receptor superfamily on the cell surface engages a signaling cascade that eventually leads to caspase activation with all subsequent subcellular events (**Figure [1](#F1){ref-type="fig"}**; [@B5]). Following ligand/receptor interaction, a multiprotein complex is formed at the plasma membrane that contains activated death receptors as well as intracellular signaling molecules that are recruited upon activation, for example FAS-associated death domain protein (FADD) and caspase-8 ([@B5]). This multiprotein complex is called the death-inducing signaling complex (DISC) and provides a signaling platform for activation of caspase-8 ([@B5]). Once activated, caspase-8 transmits the death signal by cleaving and activating downstream effector caspases such as caspase-3. Alternatively, caspase-8 can cleave other substrates besides caspases for example Bid, which results in the generation of tBid, a cleavage product with increased proapoptotic activity. tBid, in turn, translocates to mitochondrial membranes to initiate cytochrome c release. Various stress signals including DNA damage and hypoxia can engage the mitochondrial (intrinsic) pathway, leading to permeabilization of mitochondrial membranes and the release of proapoptotic proteins from the mitochondrial intermembrane space into the cytosol (**Figure [1](#F1){ref-type="fig"}**;[@B16]). For example, the release of cytochrome c from the mitochondria initiates the formation of a multiprotein complex consisting of Apaf-1, cytochrome c and caspase-9 which drives caspase-9 activation in the cytosol. Alternatively, the release of Smac (second mitochondrial activator of apoptosis) fosters caspase activation and apoptosis by neutralizing Inhibitor of Apoptosis (IAP) proteins ([@B19]).

MOLECULAR TARGETED STRATEGIES TO EXPLOIT APOPTOSIS PATHWAYS
===========================================================

Since the engagement of apoptosis signaling cascades can trigger cell death very efficiently and rapidly, there are also various brakes in order to ensure that accidental engagement of this cellular signaling network does not have detrimental effects on cell viability ([@B14]). Accordingly, a large variety of apoptosis-inhibiting factors have been identified that prevent the execution of the full cell death program upon accidental engagement of cell death pathways. While these antiapoptotic factors constitute endogenous regulators for the fine tuning of the system, they are frequently misused by human cancers to block signaling to cell death and to evade the induction of apoptosis. For example, genetic or epigenetic events can lead to aberrant overexpression of antiapoptotic molecules or, alternatively, to silencing or inactivation of proapoptotic factors with the result of a blockade of apoptosis signaling pathways ([@B14]). This implies that a better understanding of the molecular events that are responsible for the inactivation of cell death programs in human cancers can provide the basis for the development of molecular targeted therapies in order to efficiently elicit apoptotic cell death as a new therapeutic strategy. The idea to selectively target apoptosis signaling pathways in order to either directly engage cell death programs or to bypass resistance to apoptosis by neutralizing the factors that block apoptosis has in recent years already been transferred into the development of innovative treatment approaches. These concepts are currently under preclinical and clinical evaluation. On theoretical grounds, these approaches can be divided according to their primary mode of action, e.g., depending on whether they engage proapoptotic signals or antagonize antiapoptotic factors.

STRATEGY 1: ENHANCING PROAPOPTOTIC SIGNALS
------------------------------------------

One strategy to target apoptosis signaling pathways for the treatment of cancers resides in the direct activation of proapoptotic signaling pathways (**Figure [1](#F1){ref-type="fig"}**). The best know example of direct engagement of apoptosis pathways is the use of death receptor ligands, which bind to the corresponding death receptors on the cell surface. Since death receptors have a direct link to apoptosis signaling pathways, this approach can directly engage the apoptotic machinery. Among the death receptors and their ligands, the TRAIL/TRAIL receptor system has gained most attention, since it preferentially triggers cell death in cancer cells compared to non-malignant cells, providing some tumor selectivity ([@B6]; [@B22]). There are four membrane-bound TRAIL receptors, two of which transmit the apoptotic signal to intracellular signaling pathways of apoptosis ([@B5]). By comparison, two TRAIL receptors represent decoy receptors that bind TRAIL, but do not produce a proapoptotic signal and can even antagonize TRAIL-mediated apoptosis ([@B5]).

In order to target the two proapoptotic TRAIL receptors, soluble TRAIL as well as antibodies directed selectively against TRAIL receptor 1 or TRAIL receptor 2 have been reported to elicit apoptosis in childhood malignancies, e.g., in neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and leukemia ([@B39]; [@B46]; [@B28]; [@B17]; [@B10]; [@B50]; [@B13]; [@B26]; [@B1]). However, soluble TRAIL or receptor antibodies are often not sufficient as monotherapy to suppress tumor growth. For example, a fully humanized monoclonal antibody directed against TRAIL receptor 1, i.e., mapatumumab, was tested within the Pediatric Preclinical Testing Program, a National Cancer Institute initiative to identify compounds that should be prioritized for clinical evaluation in pediatric cancer ([@B41]). Limited cytotoxic effects were reported for various pediatric cancer cell lines, when mapatumumab was used in cell culture studies ([@B41]). Some antitumor activity *in vivo* was reported for mapatumumab with significant differences in event-free survival of mice treated with mapatumumab in some solid pediatric cancer models, for example osteosarcoma, neuroblastoma, and glioblastoma ([@B41]).

Based on these *in vitro* and *in vivo* studies showing that monotherapy with TRAIL ligands or TRAIL receptor antibodies are not sufficient to cause tumor regression and sustained control of tumor growth in the majority of childhood cancers, a number of different combination therapies were developed. One promising approach resides in the combination of TRAIL receptor agonists together with conventional chemotherapeutics ([@B45]; [@B27]; [@B36]; [@B48], [@B49]). The observed cooperative or synergistic interaction is considered to involve the simultaneous activation of both death receptor and mitochondrial pathways of apoptosis, resulting in enhanced activation of downstream effector caspases and, eventually, increased apoptosis. This approach of using TRAIL together with chemotherapy has been pursued in various malignancies including childhood tumors.

The evaluation of TRAIL receptor agonists against pediatric cancers is hampered by the fact that only a few studies have so far been conducted using primary tumor samples instead of established cancer cell lines. Such studies on primary tumor material are especially relevant to evaluate the antitumor activity of TRAIL receptor agonists, since it is currently unclear to what extent established cancer cell lines do in fact resemble the clinical situation. Studies testing TRAIL receptor agonists against primary tumor samples include experiments with primary neuroblastoma cells derived from children with neuroblastoma ([@B1]). Soluble TRAIL as well as TRAIL receptor 2 agonistic antibodies were shown to trigger apoptosis in primary neuroblastoma cells, in particular in combination with molecular targeted therapeutics, i.e., Smac peptides, IAP antagonists, or proteasome inhibitors ([@B18]; [@B37]; [@B1]). Furthermore, primary acute lymphoblastic leukemia (ALL) blasts obtained from children with ALL were tested for their sensitivity toward TRAIL ([@B10]; [@B11]). While 50% of these primary samples responded to treatment with TRAIL with apoptosis, the remaining 50% remained resistant toward TRAIL ([@B10]). Of note, some resistant samples eventually exhibited an increase in proliferation in response to TRAIL treatment compared to untreated controls, in line with the observation that TRAIL can paradoxically stimulate non-apoptotic signaling pathways proliferation in apoptosis-resistant cancers, for example by activating nuclear factor-kappaB (NF-κB; [@B10]). The first phase I clinical trial to evaluate a TRAIL receptor agonist against pediatric cancers was recently completed using the TRAIL-R2 monoclonal antibody lexatumumab in children with refractory solid tumors (**Table [2](#T2){ref-type="table"}**).

STRATEGY 2: NEUTRALIZING ANTIAPOPTOTIC PROTEINS
-----------------------------------------------

Another approach to exploit apoptosis signaling pathways for the treatment of pediatric cancers resides in the neutralization of antiapoptotic mechanisms that block apoptosis signaling. Depending on the status of oncogenic action of a particular tumor, this approach will either engage cell death programs or will have to be combined with additional cytotoxic principles that directly trigger cell death. Key negative regulators of apoptosis comprise the antiapoptotic proteins of the Bcl-2 family and IAP proteins.

IAP PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC CANCERS
========================================================

Inhibitor of Apoptosis proteins comprise eight human analogs including X chromosome-linked inhibitor of apoptosis protein (XIAP), cIAP1, cIAP2, survivin, apollon, livin/melanoma-IAP (ML-IAP), neuronal apoptosis inhibitory protein (NAIP), and IAP-like protein-2 (ILP-2) (**Table [1](#T1){ref-type="table"}**;[@B19]). The baculoviral IAP repeat (BIR) domain represents the unifying structural motif that is present in all IAP proteins. In addition to this BIR domain, additional functional domains of IAP proteins exist in some but not all family members. For example, the really interesting new gene (RING) domain exerts E3 ubiquitin ligase activity and is involved in ubiquitination. Despite their name, IAP proteins vary in their ability to block apoptosis. Among the IAP proteins, XIAP is considered to possess the most prominent antiapoptotic activity and inhibits caspase activation by binding to caspase-3, -7, and -9 ([@B9]). IAP proteins that harbor a RING domain can trigger proteasomal degradation of other IAP proteins or caspases via their E3 ligase activity ([@B19]). In addition, K63-linked ubiquitination results in modulation of signal transduction and, for example, activation of NF-κB by cellular inhibitor of apoptosis protein (cIAP) proteins.

###### 

List of human IAP proteins.

  Official name   Other name(s)
  --------------- ----------------
  BIRC1           NAIP
  BIRC2           cIAP1
  BIRC3           cIAP2
  BIRC4           XIAP
  BIRC5           Survivin
  BIRC6           Apollon, BRUCE
  BIRC7           ML-IAP, Livin
  BIRC8           ILP2, hILP2

Since IAP proteins block downstream effector pathways of apoptosis by inhibiting caspase activation and also impinge on critical cell survival pathways including NF-κB signaling, they represent promising targets for therapeutic intervention. Accordingly, a number of different approaches have been pursued over the last years to develop therapeutic strategies directed against IAP proteins. For example, Smac peptides and Smac mimetics have been developed to neutralize IAP proteins ([@B19]). These small molecules resemble the endogenous Smac protein, an endogenous antagonist of IAP proteins. Under physiological conditions, Smac resides within the mitochondrial intermembrane space. Upon the induction of apoptosis, Smac is released from the mitochondrial intermembrane space into the cytosol where it binds to IAP proteins and neutralizes them. Similar to Smac-related compounds, small-molecule IAP antagonists have been designed that similarly bind to IAP proteins and antagonize their function ([@B19]). Smac mimetics or IAP antagonists have been reported to either directly trigger apoptosis or to enhance apoptosis in response to death receptor ligands, cytotoxic chemotherapeutics or γ-irradiation in various childhood cancers, including leukemia, neuroblastoma, rhabdomyosarcoma, and glioblastoma ([@B18]; [@B11]; [@B33]; [@B1]; [@B32]; [@B47]). In a first proof-of-concept study in an intracranial mouse model of glioblastoma, the combined administration of Smac mimetic together with TRAIL resulted in complete eradication of glioblastoma ([@B18]). Similarly, IAP antagonists together with TRAIL exerted antileukemic activity in a non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of ALL and also acted in concert to trigger apoptosis in ALL cell lines as well as in primary blasts obtained from children with ALL ([@B11]). Furthermore, IAP antagonists synergized together with TRAIL receptor 2 antibodies, i.e., lexatumumab, to trigger apoptotic cell death in neuroblastoma cells, including primary neuroblastoma cultures derived from patient samples ([@B1]). Similar synergistic antitumor activity was observed for IAP antagonists together with lexatumumab against rhabdomyosarcoma. Besides TRAIL, IAP antagonists were also reported to act in concert with conventional chemotherapeutics, for example in childhood ALL ([@B32]).

Survivin represents another IAP protein that comprises one BIR domain without any additional functional domains ([@B4]). Besides its function in apoptosis, survivin also plays an important role in the regulation of mitosis. As far as childhood malignancies are concerned, survivin has gained considerable attention, since it is located on 17q25, a chromosomal region that is frequently amplified in neuroblastoma ([@B23]). Accordingly, overexpression of survivin was associated with advance-stage neuroblastoma as well as poor prognosis ([@B3]; [@B23]; [@B7]; [@B24]; [@B35]). Besides neuroblastoma, also childhood leukemia exhibits high expression of survivin which correlated with an enhanced risk of relapse ([@B43]). Of note, high-risk pediatric ALL also correlated with low levels of survivin-2B, since this isoform of survivin was found to promote rather than inhibit apoptosis ([@B44]). It is interesting to note that survivin has been used as a therapeutic target for immunotherapeutic strategies ([@B8]). For example, survivin served as tumor-associated antigene for stimulation of cytotoxic T cells. Also, a DNA vaccination based on survivin-associated peptides was designed that led to suppression of tumor growth upon prophylactic vaccination in a neuroblastoma *in vivo* mouse model ([@B12]). In children with relapsed ALL, a phase I clinical trial testing EZN-3042, an investigational agent that inhibits survivin protein expression, together with re-induction chemotherapy was recently conducted (**Table [2](#T2){ref-type="table"}**).

###### 

Examples of clinical trials targeting apoptosis pathways in pediatric cancers.

  Agent         Target     Trial stage   Condition                Identifier \#
  ------------- ---------- ------------- ------------------------ ---------------
  Lexatumumab   TRAIL-R2   Phase I       Pediatric solid tumors   NCT00428272
  G3139         Bcl-2      Phase I       Pediatric solid tumors   NCT00039481
  EZN-3042      Survivin   Phase I       Pediatric ALL            NCT01186328

Bcl-2 PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC TUMORS
=========================================================

Proteins of the Bcl-2 family comprise both pro- and antiapoptotic members (**Table [3](#T3){ref-type="table"}**) and play an important role in the regulation of the intrinsic pathway of apoptosis ([@B2]). Accordingly, pro- and antiapoptotic Bcl-2 proteins are critical regulators of mitochondrial outer membrane permeabilization by regulating the release of mitochondrial intermembrane proteins into the cytosol. Antiapoptotic Bcl-2 proteins such as Bcl-2, Bcl-X~L~, and Mcl-1 are often overexpressed in human cancers including childhood malignancies. Since the efficacy of chemotherapy largely depends on intact apoptosis signaling pathways, in particular mitochondria-mediated apoptosis overexpression of antiapoptotic Bcl-2 proteins has been linked to chemoresistance. Consequently, targeting of antiapoptotic Bcl-2 proteins is considered to provide a promising approach for chemosensitization of human cancers ([@B16]). To target antiapoptotic Bcl-2 proteins, small-molecule inhibitors have been developed. For example, ABT-737 represents such a small-molecule inhibitor that binds to Bcl-2, Bcl-X~L~, and Bcl-w ([@B38]). The corresponding orally available analog ABT-263 was evaluated by the Pediatric Preclinical Testing Program ([@B30]). Interestingly, the most potent antitumor activity of ABT-263 was observed against childhood ALL both *in vitro* and *in vivo* with complete remission in 50% of cases ([@B30]). In addition, ABT-737 potentiated chemotherapy-mediated cell death, for example together with standard cytotoxic compounds used in childhood ALL including vincristin, L-asparaginase, and glycocorticoids ([@B25]). This cooperative antileukemic activity of ABT-737 together with chemotherapeutics was even observed in cases of drug resistance ([@B25]), indicating that the addition of ABT-737 may overcome some forms of chemoresistance in ALL. However, Bcl-X~L~-targeting compounds can also exert mechanism-based toxicity by inducing platelet death and subsequently thrombocytopenia ([@B34]), which may limit their clinical use in childhood cancers. Moreover, BH3 peptidomimetics that antagonize antiapoptotic Bcl-2 proteins showed antitumor activity as single agents against neuroblastoma ([@B21]). Interestingly, high expression levels of Bcl-2 or Mcl-1 correlated with advanced disease in neuroblastoma ([@B29]). Knockdown studies underscored the important role of Mcl-1 for chemoresistance, since downregulation of Mcl-1 conferred sensitivity to chemotherapeutics. *In vitro* profiling of neuroblastoma cells using BH3-domain peptides revealed that, in addition to Mcl-1, also other antiapoptotic Bcl-2 proteins can confer resistance to chemotherapy ([@B20]). In addition to the small-molecule inhibitors, also Bcl-2 antisense oligonucleotides, for example G3139, showed antitumor activity in pediatric malignancies. For example, a phase I trial was conducted in children with recurrent solid malignancies together with chemotherapeutics (i.e., doxorubicin, cyclophosphamide) that demonstrated biologic activity of G3139 ([@B40]; **Table [2](#T2){ref-type="table"}**). Together, these studies indicate that the mitochondrial pathway of apoptosis may represent a promising therapeutic target in childhood cancers.

###### 

List of human Bcl-2 proteins.

  Antiapoptotic   Proapoptotic
  --------------- --------------
  Bcl-2           Bax
  Bcl-x~L~        Bak
  Bcl-w           Bad
  Bcl-B           Bid
  Mcl-1           Bim
  A1              Bik
                  Bmf
                  Noxa
                  Puma
                  Hrk

CONCLUSION
==========

Based on the concept that apoptotic signaling pathways are central regulators of cell death in cancers and upon cancer therapy, dysregulation of this program can lead to cancer resistance. Therefore, the identification of molecular targets that can be exploited in the design of novel anticancer strategies yielded several promising targets for therapeutic intervention. Furthermore, these strategies are already under evaluation in early clinical trials. Therefore, the knowledge on apoptosis signaling pathways and their deregulation in pediatric malignancies may open new perspectives for more effective treatment approaches for children with cancer.
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